A study published by The Lancet Regional Health, a European journal, went on to publish the study after gathering data from the Public Health of Sweden, which is the National Board of Health, and welfares, and the statistics of Sweden.
A recent study conducted by the National Board of Health and welfares of Sweden said that the one’s those who have been vaccinated with the first dose of the Oxford-AstraZeneca Covid-19 vaccine, which is followed by an mRNA dose of vaccine shot, have a very low risk of infection and are at low risk of getting covid-19 as compared to the once those who have received both the jab shots of AstraZeneca preventive, according to nationwide study which Sweden conducts. The use of AstraZeneca’s vector-based vaccine against the Covid-19 was decided for the people who were younger than 65 years of age and as because it is safe and keeping that in mind, every individual below the age of 45, those who were given the AstraZeneca was given mRNA as the second dose of the vaccine. Professor Peter Nordstorm at the Umea University in Sweden said that “Having received any of the approved vaccines is better compared to no vaccine, and two doses are better than one.”
He further went on to say that, “However, our study shows a greater risk reduction for people who received an mRNA vaccine after having received the first dose of a vector-based, as compared to people having received the vector-based vaccine for both doses.” The study was published on Monday in the Lancet Regional Health, a European journal. The study was conducted based on the nationwide registry data collected from the public Health Agency of Sweden and the National Board of Health and Welfare and statistics of Sweden. The main analysis was based on the 7000,000 individuals who were included. During the 2.5 month average follow-up period of the second dose, the study further showed that the risks of infection are 67% lower because the dose was combined with AstraZeneca and Pfizer vaccines. The researchers said that the risk of reduction was less by 50% for those who have received the two doses of the AstraZeneca vaccine, which is known as Covishield in India. Since the beginning of the vaccination drive in the country, around 69.26 crores of citizens have been vaccinated with the first dose of the vaccine, and around 27.88 crores of citizens, have received both doses of the vaccine.
The researchers observed the risk estimates after the difference in the date of the vaccination, the difference in age, the socio-economic status, and the other factors that could lead to the risk of Covid-19. During the study, the researchers even noticed that the study also estimates the effectiveness of application with the Delta variant, which dominated the conformed cases during the follow-up period. According to the previous studies conducted, the mix-and-match of the vaccines results in a robust immune system, and it is also an effective alternative for the increase of the immunity with the body cells to fight against Covid-19 and even including the Delta variant. Marcel Ballin, a doctorate student at Umea University and is also the co-author of this study, said that the study results have direct implications for the vaccination strategies within the different countries. Furthermore, in another statement was mentioned that “The World Health Organization has stated that despite the promising results from previous studies regarding the immune response from mix-and-match vaccination, there is a need for larger studies to investigate their safety and effectiveness against clinical outcomes. Here we now have one such study,”
The researchers even mentioned that there are low chances of thromboembolic incidents or even the formation of the blood clots that could occur in the blood vessel for every vaccination schedule. But on the other hand, it is still unclear which extent these schedules may lead to the risk of clinical infections, said the researchers.
